Literature DB >> 10718940

Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitis. SEIEVA collaborating Group.

A Mele1, M E Tosti, A Marzolini, A Moiraghi, P Ragni, G Gallo, E Balocchini, F Santonastasi, T Stroffolini.   

Abstract

Using data from the surveillance system for type-specific acute viral hepatitis, the temporal incidence trend of non-A, non-B acute hepatitis and risk factors for acute hepatitis C have been evaluated in Italy. The association between hepatitis C and the potential risk factors (odds ratios, OR) was estimated using hepatitis A patients as controls. The independent roles of the different risk factors were estimated by multiple logistic regression analysis. The incidence of non-A, non-B acute hepatitis declined from 5 per 100 000 to 1 per 100 000 between 1985 and 1996. Anti-HCV data collected by SEIEVA since 1991 showed that 60% of patients with non-A, non-B acute hepatitis were positive for antibodies to the hepatitis C virus (anti-HCV) at the time of hospitalization. During the 6 months prior to the disease onset, the most frequently reported risk factors were multiple sexual partners, other parenteral exposure and intravenous drug use; transmission by blood transfusion declined from 20% in 1985 to 2% in 1996. On multivariate analysis, intravenous drug use (OR=35.5; 95% CI=23.1-54.4), surgical intervention (OR=4.6; 95% CI=3.3-6.5), dental treatment (OR=1.5; 95% CI=1.1-1.9) and two or more sexual partners (OR=2.2; 95% CI=1.6-3.0) were all independent predictors of hepatitis C. These findings indicate that HCV infection is decreasing in Italy. Intravenous drug use, multiple sexual partners, surgical intervention and dental therapy are the main modes of transmission.

Entities:  

Mesh:

Year:  2000        PMID: 10718940     DOI: 10.1046/j.1365-2893.2000.00179.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  10 in total

Review 1.  Treatment of acute HCV infection.

Authors:  Jason Grebely; Gail V Matthews; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-22       Impact factor: 46.802

2.  Transmission of hepatitis C virus in a gynecological surgery setting.

Authors:  M Massari; N Petrosillo; G Ippolito; L Solforosi; L Bonazzi; M Clementi; A Manzin
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

3.  Prevalence and risk factors for hepatitis C infection in rural north Vietnam.

Authors:  Van Thi Thuy Nguyen; Mary-Louise McLaws; Gregory J Dore
Journal:  Hepatol Int       Date:  2007-07-19       Impact factor: 6.047

4.  Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population.

Authors:  L A Kondili; P Chionne; A Costantino; U Villano; C Lo Noce; F Pannozzo; A Mele; S Giampaoli; M Rapicetta
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 5.  Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis.

Authors:  L M Kucirka; H Sarathy; P Govindan; J H Wolf; T A Ellison; L J Hart; R A Montgomery; R L Ros; D L Segev
Journal:  Am J Transplant       Date:  2011-03-14       Impact factor: 8.086

6.  Acute hepatitis C virus infection in a nurse trainee following a needlestick injury.

Authors:  Renzo Scaggiante; Liliana Chemello; Roberto Rinaldi; Giovanni Battista Bartolucci; Andrea Trevisan
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

7.  High Prevalence of Hepatitis C virus Among Injection Drug Users in Zhenjiang, Jiangsu, China.

Authors:  Nana Wu; Qinjuan Ge; Qingchuan Feng; Jun Zhang; Xiaoxia Liu; Caihong Sun; Yongkang Xu; Guangli He; Chiyu Zhang
Journal:  Indian J Virol       Date:  2011-06-30

8.  Prevalence of HCV among the high risk groups in Khyber Pakhtunkhwa.

Authors:  Ijaz Ali; Lubna Siddique; Latif U Rehman; Najib U Khan; Aqib Iqbal; Iqbal Munir; Farzana Rashid; Sana U Khan; Safira Attache; Zahoor A Swati; Mehwish S Aslam
Journal:  Virol J       Date:  2011-06-11       Impact factor: 4.099

9.  Prevalence of HCV Infections and Co-Infection With HBV and HIV and Associated Risk Factors Among Addicts in Drug Treatment Centers, Lorestan Province, Iran.

Authors:  Hossein Norouzian; Mohammadreza Gholami; Pegah Shakib; Gholamreza Goudarzi; Hamze Ghobadian Diali; Azam Rezvani
Journal:  Int J High Risk Behav Addict       Date:  2016-01-18

10.  Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist.

Authors:  A Nappi; A Perrella; P Bellopede; A Lanza; A Izzi; M Spatarella; C Sbreglia
Journal:  Infect Agent Cancer       Date:  2017-02-07       Impact factor: 2.965

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.